PPARγ expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway

Lupus

Volumn 20, Issue 6, 2011, Pages 575-587

  Oxer, D S ^a   Godoy, L C ^b   Borba, E ^a   Lima Salgado, T ^a   Passos, L A ^a   Laurindo, I ^a   Kubo, S ^a   Barbeiro, D F ^a   Fernandes, D ^a   Laurindo, F R ^a   Velasco, I T ^a   Curi, R ^a   Bonfa, E ^a   Souza, H P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

autoimmune disease; CD36; CD80; cytokines; inflammation

Indexed keywords

CD40 LIGAND; CHLOROQUINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PREDNISONE; SMALL INTERFERING RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; GENE ACTIVATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGENS, CD40; CASE-CONTROL STUDIES; CD40 LIGAND; CELL LINE, TUMOR; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MIDDLE AGED; MONOCYTES; POLYMERASE CHAIN REACTION; PPAR GAMMA; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; YOUNG ADULT;

EID: 79956122674     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203310392419     Document Type: Article

References (57)

1. Isenberg D, Dudeney C, Wojnaruska F, et al. Detection of cross reactive anti-DNA antibody idiotypes on tissue-bound immunoglobulins from skin biopsies of lupus patients. J Immunol. 1985 ; 135: 261-264 (Pubitemid 15011439)
2. Munoz LE, Chaurio RA, Gaipl US, Schett G, Kern P. MoMa from patients with systemic lupus erythematosus show altered adhesive activity. Autoimmunity. 2009 ; 42: 269-271
3. Gaipl US, Munoz LE, Grossmayer G, et al. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun. 2007 ; 28: 114-121 (Pubitemid 46680499)
4. Funauchi M, Yoo BS, Nozaki Y, et al. Dysregulation of the granulocyte-macrophage colony-stimulating factor receptor is one of the causes of defective expression of CD80 antigen in systemic lupus erythematosus. Lupus. 2002 ; 11: 317-321 (Pubitemid 34627436)
5. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus. 2004 ; 13: 391-397 (Pubitemid 38788502)
6. Bishop GA, Warren WD, Berton MT. Signaling via major histocompatibility complex class II molecules and antigen receptors enhances the B cell response to gp39/CD40 ligand. Eur J Immunol. 1995 ; 25: 1230-1238
7. Brines RD, Klaus GG. Polyclonal activation of immature B cells by preactivated T cells: the role of IL-4 and CD40 ligand. Int Immunol. 1993 ; 5: 1445-1450 (Pubitemid 23325200)
8. Dohnal AM, Luger R, Paul P, Fuchs D, Felzmann T. CD40 ligation restores type 1 polarizing capacity in TLR4 activated dendritic cells that have ceased interleukin-12 expression. J Cell Mol Med. 2009 ; 13: 1741-1750
9. Souza HP, Frediani D, Cobra AL, et al. Angiotensin II modulates CD40 expression in vascular smooth muscle cells. Clin Sci (Lond). 2009 ; 116: 423-431
10. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000 ; 67: 2-17 (Pubitemid 30046812)
11. Xu Y, Song G. The role of CD40-CD154 interaction in cell immunoregulation. J Biomed Sci. 2004 ; 11: 426-438 (Pubitemid 38721026)
12. Datta SK, Kaliyaperumal A, Mohan C, Desai-Mehta A. T helper cells driving pathogenic anti-DNA autoantibody production in lupus: nucleosomal epitopes and CD40 ligand signals. Lupus. 1997 ; 6: 333-336 (Pubitemid 27160660)
13. Grammer AC, Lipsky PE. CD154-CD40 interactions mediate differentiation to plasma cells in healthy individuals and persons with systemic lupus erythematosus. Arthritis Rheum. 2002 ; 46: 1417-1429 (Pubitemid 34620186)
14. Mohan C, Shi Y, Laman JD, Datta SK. Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol. 1995 ; 154: 1470-1480
15. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK, Routsias JG. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun. 2006 ; 26: 165-171 (Pubitemid 43737334)
16. Davidson A, Wang X, Mihara M, et al. Co-stimulatory blockade in the treatment of murine systemic lupus erythematosus (SLE). Ann N Y Acad Sci. 2003 ; 987: 188-198 (Pubitemid 36584022)
17. Eisenberg R. Why can't we find a new treatment for SLE?. J Autoimmun. 2009 ; 32: 223-230
18. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol. 2003 ; 65: 261-311 (Pubitemid 38249155)
19. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994 ; 79: 1147-1156
20. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998 ; 273: 25573-25580 (Pubitemid 28475776)
21. Guyton K, Zingarelli B, Ashton S, et al. Peroxisome proliferator- activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. Shock. 2003 ; 20: 56-62
22. Hasegawa H, Takano H, Zou Y, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J Mol Cell Cardiol. 2005 ; 38: 257-265 (Pubitemid 40215195)
23. Mathur RK, Awasthi A, Saha B. The conundrum of CD40 function: host protection or disease promotion?. Trends Parasitol. 2006 ; 22: 117-122 (Pubitemid 43290226)
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277 (Pubitemid 13221242)
25. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
26. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 ; 31: 1250-1256 (Pubitemid 36444440)
27. Hegde P, Qi R, Abernathy K, et al. A concise guide to cDNA microarray analysis. Biotechniques. 2000 ; 29: 548-550, 52-54, 56 passim
28. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000 ; 132: 365-386
29. Ferro D, Pignatelli P, Loffredo L, et al. Soluble CD154 plasma levels in patients with systemic lupus erythematosus: modulation by antiphospholipid antibodies. Arthritis Rheum. 2004 ; 50: 1693-1694 (Pubitemid 38608094)
30. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998 ; 93: 241-252 (Pubitemid 28180857)
31. Roy M, Aruffo A, Ledbetter J, Linsley P, Kehry M, Noelle R. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Eur J Immunol. 1995 ; 25: 596-603
32. Aprahamian T, Bonegio RG, Richez C, et al. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol. 2009 ; 182: 340-346
33. Venegas-Pont M, Sartori-Valinotti JC, Maric C, et al. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol. 2009 ; 296: R1282-1289
34. Zhao W, Thacker SG, Hodgin JB, et al. The peroxisome proliferator- activated receptor {gamma} agonist pioglitazone improves cardiometabolic risk and renal inflammation in murine lupus. J Immunol. 2009 ; 15;183: 2729-2740
35. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997 ; 96: 396-399 (Pubitemid 27329409)
36. She QM, Zhao J, Wang XL, Zhou CM, Shi XZ. Effect of dexamethasone on peroxisome proliferator activated receptor-gamma mRNA expression in 3T3-L1 adipocytes with the human recombinant adiponectin. Chin Med J (Engl). 2007 ; 120: 155-158 (Pubitemid 46584916)
37. Guo C, Ricchiuti V, Lian BQ, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008 ; 117: 2253-2261
38. Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum. 2010 ; 39: 491-503
39. Janko C, Schorn C, Grossmayer GE, et al. Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev. 2008 ; 8: 9-12
40. Kuroiwa T, Schlimgen R, Illei GG, Boumpas DT. Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. Clin Immunol. 2003 ; 106: 65-72 (Pubitemid 36263304)
41. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol. 2002 ; 103: 54-62 (Pubitemid 34478420)
42. Dinarello CA. Proinflammatory cytokines. Chest. 2000 ; 118: 503-508 (Pubitemid 30637822)
43. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997 ; 272: 18779-18789 (Pubitemid 27318225)
44. Jeon YJ, Han SH, Lee YW, Lee M, Yang KH, Kim HM. Dexamethasone inhibits IL-1 beta gene expression in LPS-stimulated RAW 264.7 cells by blocking NF-kappa B/Rel and AP-1 activation. Immunopharmacology. 2000 ; 48: 173-183 (Pubitemid 30608674)
45. Necela BM, Su W, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages. Immunology. 2008 ; 125: 344-358
46. Feingold KR, Moser A, Patsek SM, Shigenaga JK, Grunfeld C. Infection decreases fatty acid oxidation and nuclear hormone receptors in the diaphragm. J Lipid Res. 2009 ; 50: 2055-2063
47. Van Gool SW, Vandenberghe P, de Boer M, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev. 1996 ; 153: 47-83 (Pubitemid 27010763)
48. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994 ; 8: 1224-1234
49. Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol. 2002 ; 71: 388-400
50. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol. 2002 ; 2: 748-759 (Pubitemid 37328715)
51. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998 ; 93: 229-240 (Pubitemid 28180856)
52. Khanolkar MP, Morris RH, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 2008 ; 197: 718-724 (Pubitemid 351417869)
53. Ray DM, Akbiyik F, Bernstein SH, Phipps RP. CD40 engagement prevents peroxisome proliferator-activated receptor gamma agonist-induced apoptosis of B lymphocytes and B lymphoma cells by an NF-kappaB-dependent mechanism. J Immunol. 2005 ; 174: 4060-4069 (Pubitemid 40395982)
54. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, Phipps RP. Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood. 2004 ; 104: 1361-1368 (Pubitemid 39166512)
55. Hu Q, Zhang XJ, Zhang C, et al. Peroxisome proliferator-activated receptor-gamma1 gene therapy attenuates atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice. Hum Gene Ther. 2008 ; 19: 287-299 (Pubitemid 351442726)
56. Martins de Lima T, Gorjao R, Hatanaka E, et al. Mechanisms by which fatty acids regulate leucocyte function. Clin Sci (Lond). 2007 ; 113: 65-77 (Pubitemid 47066026)
57. Davies SS, Pontsler AV, Marathe GK, et al. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem. 2001 ; 276: 16015-16023